Defective endomitosis during megakaryopoiesis leads to thrombocytopenia in Fanca-/- mice

Blood

Volumn 124, Issue 24, 2014, Pages 3613-3623

  Pawlikowska, Patrycja ^a,b,c,d   Fouchet, Pierre ^a,e,f   Vainchenker, William ^a,c,d,g   Rosselli, Filippo ^a,b,c,d   Naim, Valeria ^a,b,c,d  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Gustave Roussy Comprehensive Cancer Institute   (France)

^c Team Metabolism   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e DIF   (France)

^f Universite Paris Sud   (France)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA GROUP A PROTEIN; FIBRINOGEN RECEPTOR; PROTEIN P16; PROTEIN P21; RETROVIRUS VECTOR; RHO KINASE; FANCA PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL AGING; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CHROMOSOMAL INSTABILITY; CHROMOSOME BREAKAGE; CLONOGENIC ASSAY; COLONY FORMING UNIT; COLONY FORMING UNIT GM; COMMITTED MYELOID PROGENITOR; CONTROLLED STUDY; CYTOKINESIS; DNA DAMAGE; DNA REPLICATION; ENDOMITOSIS; ENDOREDUPLICATION; FANCONI ANEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; G1 PHASE CELL CYCLE CHECKPOINT; HEMATOPOIETIC STEM CELL; MEGAKARYOCYTE; MEGAKARYOPOIESIS; METAPHASE; MITOSIS; MONONUCLEAR CELL; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; NUCLEAR DIVISION; PHENOTYPE; PLOIDY; POLYPLOIDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; WILD TYPE; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; CELL AGING; CHROMOSOMAL INSTABILITY; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; GENE EXPRESSION REGULATION; MEGAKARYOCYTES; MICE; MICE, KNOCKOUT; MITOSIS; THROMBOCYTOPENIA; THROMBOPOIESIS;

EID: 84915819239     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-551457     Document Type: Article

References (32)

1. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol. 2006;134(5):453-466.
2. Steinman RA. Cell cycle regulators and hematopoiesis. Oncogene. 2002;21(21):3403-3413.
3. Sakaguchi H, Nakanishi K, Kojima S. Inherited bone marrow failure syndromes in 2012. Int J Hematol. 2013;97(1):20-29.
4. Kee Y, D'Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 2010;24(16):1680-1694.
5. Naim V, Rosselli F. The FANC pathway and BLM collaborate during mitosis to prevent micronucleation and chromosome abnormalities. Nat Cell Biol. 2009;11(6):761-768.
6. Naim V, Rosselli F. The FANC pathway and mitosis: a replication legacy. Cell Cycle. 2009;8(18):2907-2911.
7. Lordier L, Pan J, Naim V, et al. Presence of a defect in karyokinesis during megakaryocyte endomitosis. Cell Cycle. 2012;11(23):4385-4389.
8. Cheng NC, van de Vrugt HJ, van der Valk MA, et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet. 2000;9(12):1805-1811.
9. Bakker ST, de Winter JP, te Riele H. Learning from a paradox: recent insights into Fanconi anaemia through studying mouse models. Dis Model Mech. 2013;6(1):40-47.
10. Río P, Segovia JC, Hanenberg H, et al. In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice. Blood. 2002;100(6):2032-2039.
11. Santaguida M, Schepers K, King B, et al. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell. 2009;15(4):341-352.
12. Strassel C, Eckly A, Léon C, et al. Hirudin and heparin enable efficient megakaryocyte differentiation of mouse bone marrow progenitors. Exp Cell Res. 2012;318(1):25-32.
13. Pawlikowska P, Leray I, de Laval B, et al. ATM-dependent expression of IEX-1 controls nuclear accumulation of Mcl-1 and the DNA damage response. Cell Death Differ. 2010;17(11):1739-1750.
14. Le Tallec B, Millot GA, Blin ME, Brison O, Dutrillaux B, Debatisse M. Common fragile site profiling in epithelial and erythroid cells reveals that most recurrent cancer deletions lie in fragile sites hosting large genes. Cell Reports. 2013;4(3):420-428.
15. Pronk CJH, Rossi DJ, Ma˚nsson R, et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell. 2007;1(4):428-442.
16. Besancenot R, Chaligné R, Tonetti C, et al. A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol. 2010;8(9).
17. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400-414.
18. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002;109(3):335-346.
19. Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479(7372):232-236.
20. Vinciguerra P, Godinho SA, Parmar K, Pellman D, D'Andrea AD. Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells. J Clin Invest. 2010;120(11):3834-3842.
21. Lordier L, Jalil A, Aurade F, et al. Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood. 2008;112(8):3164-3174.
22. Chang Y, Auradé F, Larbret F, et al. Proplatelet formation is regulated by the Rho/ROCK pathway. Blood. 2007;109(10):4229-4236.
23. Avanzi MP, Chen A, He W, Mitchell WB. Optimizing megakaryocyte polyploidization by targeting multiple pathways of cytokinesis. Transfusion. 2012;52(11):2406-2413.
24. Kosako H, Yoshida T, Matsumura F, Ishizaki T, Narumiya S, Inagaki M. Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and not ezrin/radixin/moesin proteins at the cleavage furrow. Oncogene. 2000;19(52):6059-6064.
25. Parmar K, Kim J, Sykes SM, et al. Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells. 2010;28(7):1186-1195.
26. Barroca V, Mouthon MA, Lewandowski D, et al. Impaired functionality and homing of Fancg-deficient hematopoietic stem cells. Hum Mol Genet. 2012;21(1):121-135.
27. Garaycoechea JI, Crossan GP, Langevin F, Daly M, Arends MJ, Patel KJ. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature. 2012;489(7417):571-575.
28. Otsuki T, Nagakura S, Wang J, Bloom M, Grompe M, Liu JM. Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice. J Cell Physiol. 1999;179(1):79-86.
29. Milsom MD, Lee AW, Zheng Y, Cancelas JA. Fanca-/- hematopoietic stem cells demonstrate a mobilization defect which can be overcome by administration of the Rac inhibitor NSC23766. Haematologica. 2009;94(7):1011-1015.
30. Crossan GP, van der Weyden L, Rosado IV, et al; Sanger Mouse Genetics Project. Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat Genet. 2011;43(2):147-152.
31. Ceccaldi R, Parmar K, Mouly E, et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell. 2012;11(1):36-49.
32. Gao Y, Smith E, Ker E, et al. Role of RhoA-specific guanine exchange factors in regulation of endomitosis in megakaryocytes. Dev Cell. 2012;22(3):573-584.